Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort
Authors' conclusion
In our large, monocentric cohort, the overall 24 month DRR for JAKi was greater than 80%. No significant differences in retention were found among different JAKi. Persistence was lower in patients who had previously been treated with other bDMARDs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) treated with at least one Janus kinase inhibitors (JAKi) and followed up at a single centre463 therapy courses
- Participants
- 365 patients
- Exposure
- Tofacitinib vs baricitinib vs upadacitinib vs filgotinib
- Outcome
- Drug retention rate (DRR) of each JAKi
- Follow-up
- 24 months
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
DRR
Overall DRR
86%
Observational data: associations, not effects.
Further findings
Baseline predictor of treatment discontinuation: previous biological disease-modifying anti-rheumatic drug (bDMARD)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Previous bDMARDOnly baseline predictor | 1.65 (1.08–2.53) | P = 0.021 | |
| 0.20.5125Hazard ratio (log scale) |
Disease Activity Score-C-reactive protein (DAS28-CRP) and Clinical Disease Activity Index (CDAI) · 1 year
- Significant reductions in DAS28-CRP and CDAI 1 year after treatment start
Treatment duration
- Mean treatment duration (months)
- 24 ± 17
- Maximum treatment duration (months)
- 70
Original publication
Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort. Scand J Rheumatol. Published 4 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →